European Heart Journal

(The H4-Index of European Heart Journal is 97. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 500 papers]. The publications cover those that have been published in the past four years, i.e., from 2019-12-01 to 2023-12-01.)
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure4585
2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)4449
2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation2503
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice2040
2021 ESC/EACTS Guidelines for the management of valvular heart disease1693
2020 ESC Guidelines for the management of adult congenital heart disease786
2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy726
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension714
2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease703
Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus 689
COVID-19 is, in the end, an endothelial disease633
Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era629
European Society of Cardiology: Cardiovascular Disease Statistics 2019621
2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death506
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the Internatio504
Coronaviruses and the cardiovascular system: acute and long-term implications497
Acute pulmonary embolism and COVID-19 pneumonia: a random association?460
Decline of acute coronary syndrome admissions in Austria since the outbreak of COVID-19: the pandemic response causes cardiac collateral damage423
Coronavirus fulminant myocarditis treated with glucocorticoid and human immunoglobulin392
Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy390
SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe368
Acute myocarditis presenting as a reverse Tako-Tsubo syndrome in a patient with SARS-CoV-2 respiratory infection362
Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin–angiotensin–aldosterone inhibitors357
Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases349
Sex differences in heart failure348
Characteristics and clinical significance of myocardial injury in patients with severe coronavirus disease 2019342
An EAPCI Expert Consensus Document on Ischaemia with Non-Obstructive Coronary Arteries in Collaboration with European Society of Cardiology Working Group on Coronary Pathophysiology & Microcircula332
Pathological features of COVID-19-associated myocardial injury: a multicentre cardiovascular pathology study322
SARS-CoV2: should inhibitors of the renin–angiotensin system be withdrawn in patients with COVID-19?287
Valve Academic Research Consortium 3: updated endpoint definitions for aortic valve clinical research281
The ‘Digital Twin’ to enable the vision of precision cardiology279
Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study277
Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis276
European Society of Cardiology: cardiovascular disease statistics 2021265
Sleep patterns, genetic susceptibility, and incident cardiovascular disease: a prospective study of 385 292 UK biobank participants246
Patterns of myocardial injury in recovered troponin-positive COVID-19 patients assessed by cardiovascular magnetic resonance245
Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Ather244
Corrigendum to: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force240
The ‘Ten Commandments’ for the 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation236
COVID-19-related myocarditis in a 21-year-old female patient236
Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus234
Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial233
Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement224
Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine221
2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery218
Cell type-specific expression of the putative SARS-CoV-2 receptor ACE2 in human hearts217
C-reactive protein and clinical outcomes in patients with COVID-19212
Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis196
Pulmonary embolism in COVID-19 patients: a French multicentre cohort study188
COVID-19 kills at home: the close relationship between the epidemic and the increase of out-of-hospital cardiac arrests171
Effects of tobacco cigarettes, e-cigarettes, and waterpipe smoking on endothelial function and clinical outcomes167
Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement167
Inflamm-ageing: the role of inflammation in age-dependent cardiovascular disease163
SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions162
Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyc162
Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study160
Life-threatening cardiac tamponade complicating myo-pericarditis in COVID-19156
Corrigendum to: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure o153
Targeting cardiovascular inflammation: next steps in clinical translation152
Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation and coexistent atrial fibrillation – Dual versus triple antithrombotic therapy150
Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)150
Sex and gender in cardiovascular medicine: presentation and outcomes of acute coronary syndrome147
Comparison of newer generation self-expandable vs. balloon-expandable valves in transcatheter aortic valve implantation: the randomized SOLVE-TAVI trial142
Clinical impact of conduction disturbances in transcatheter aortic valve replacement recipients: a systematic review and meta-analysis141
Corrigendum to: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS)136
Eight-year outcomes for patients with aortic valve stenosis at low surgical risk randomized to transcatheter vs. surgical aortic valve replacement136
Typical takotsubo syndrome triggered by SARS-CoV-2 infection134
The neutrophil–lymphocyte ratio and incident atherosclerotic events: analyses from five contemporary randomized trials133
Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry129
A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial129
Effects of dapagliflozin in DAPA-HF according to background heart failure therapy128
Isolated tricuspid valve surgery: impact of aetiology and clinical presentation on outcomes126
Corrigendum to: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS)126
Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction126
The Mediterranean diet, plasma metabolome, and cardiovascular disease risk125
Left bundle branch area pacing outcomes: the multicentre European MELOS study124
Cardiovascular health after menopause transition, pregnancy disorders, and other gynaecologic conditions: a consensus document from European cardiologists, gynaecologists, and endocrinologists117
Remnant cholesterol predicts cardiovascular disease beyond LDL and ApoB: a primary prevention study116
Prevalence and outcome of dual aortic stenosis and cardiac amyloid pathology in patients referred for transcatheter aortic valve implantation114
Multicentre, randomized comparison of two-stent and provisional stenting techniques in patients with complex coronary bifurcation lesions: the DEFINITION II trial113
Heart failure drug treatment: the fantastic four113
The ESC Clinical Practice Guidelines for the Management of Adult Congenital Heart Disease 2020111
The physical activity paradox in cardiovascular disease and all-cause mortality: the contemporary Copenhagen General Population Study with 104 046 adults109
Mortality after drug-eluting stents vs. coronary artery bypass grafting for left main coronary artery disease: a meta-analysis of randomized controlled trials109
Associations between gut microbiota, faecal short-chain fatty acids, and blood pressure across ethnic groups: the HELIUS study108
Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial107
Prevalence of statin intolerance: a meta-analysis106
Screening for atrial fibrillation: a call for evidence105
Clinical characteristics, diagnosis, and risk stratification of pulmonary hypertension in severe tricuspid regurgitation and implications for transcatheter tricuspid valve repair105
Thin-cap fibroatheroma predicts clinical events in diabetic patients with normal fractional flow reserve: the COMBINE OCT–FFR trial104
European Heart Rhythm Association (EHRA) international consensus document on how to prevent, diagnose, and treat cardiac implantable electronic device infections—endorsed by the Heart Rhythm Society (104
The European bifurcation club Left Main Coronary Stent study: a randomized comparison of stepwise provisional vs. systematic dual stenting strategies (EBC MAIN)103
Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials102
Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF102
Senescence-induced inflammation: an important player and key therapeutic target in atherosclerosis100
Multi-organ assessment in mainly non-hospitalized individuals after SARS-CoV-2 infection: The Hamburg City Health Study COVID programme100
Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes99
Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial97
AV junction ablation and cardiac resynchronization for patients with permanent atrial fibrillation and narrow QRS: the APAF-CRT mortality trial97
TRI-SCORE: a new risk score for in-hospital mortality prediction after isolated tricuspid valve surgery97